NCT04415944 2026-03-19
HIPEC
Wake Forest University Health Sciences
Phase 2 Completed
Clinical Trials
27 trialsNCT06412510 2026-03-18
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07480954 2026-03-18
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT05763199 2026-03-12
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
University of California, Davis
Phase 2 Active not recruiting
NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07454018 2026-03-06
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT06819007 2026-03-05
DO-01
Daiichi Sankyo
Phase 3 Recruiting
NCT03393884 2026-02-27
OVATION 2
Imunon
Phase 1/2 Active not recruiting
NCT06240598 2026-02-27
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06915025 2026-02-27
OVATION-3
Imunon
Phase 3 Recruiting
NCT07432633 2026-02-25
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
Phase 1/2 Recruiting
NCT06890338 2026-02-24
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting
NCT07334119 2026-02-19
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Phase 1 Recruiting
NCT05316181 2026-02-12
KOV-HIPEC-02R
National Cancer Center, Korea
Phase 3 Active not recruiting
NCT05238922 2026-02-10
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT05937620 2026-02-09
Melisa-II
Fundacion Clinic per a la Recerca Biomédica
Phase NA Recruiting
NCT06386887 2026-02-09
Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
Case Comprehensive Cancer Center
Phase NA Recruiting
NCT06469281 2026-02-03
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Regeneron Pharmaceuticals
Phase 1 Recruiting
NCT07303894 2026-01-29
A Study of Isoquercetin in People With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT01439659 2026-01-16
Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07218809 2026-01-16
TREVI-OC-01
AstraZeneca
Phase 3 Recruiting
NCT07341100 2026-01-14
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Not yet recruiting
NCT06173037 2026-01-07
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed
NCT06690775 2025-12-23
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
TORL Biotherapeutics, LLC
Phase 2 Recruiting
NCT04670068 2025-12-22
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting